Information Provided By: 
Fly News Breaks for February 21, 2019
MYOK
Feb 21, 2019 | 17:14 EDT
BMO Capital analyst George Farmer initiated MyoKardia with an Outperform rating and $85 price target. The analyst said he would be a buyer on his view of the potential of lead drug, mavacamten, for treatment of hypertrophic cardiomyopathy. He added that the recent stock pullback caused by the loss of Sanofi (SNY) as an entrenched partner, which he believes mostly had to do with Sanofi pipeline re-prioritization, creates an attractive entry point for investment in MyoKardia.
News For MYOK From the Last 2 Days
There are no results for your query MYOK
